Wednesday 29 April 2020

FDA Appproved Ibrutinib-rituximab Combo for Leukemia After E1912 Trial

E1912, a phase 3 trial, showed ibrutinib plus rituximab combination as a new treatment option for untreated patients (aged 70 or younger) with chronic lymphocytic leukemia.


from Medindia Health News https://ift.tt/2ycaVSo

No comments:

Post a Comment